Company Description
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system.
The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity.
It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension.
It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Punit S. Dhillon B.A. |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | (858) 410-0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | Executive Chairman, President, Chief Executive Officer and Secretary |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Tuan Tu Diep M.Sc. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | EFFECT | Notice of Effectiveness |
| May 17, 2024 | EFFECT | Notice of Effectiveness |
| May 17, 2024 | 424B3 | Prospectus |
| May 10, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 10, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 10, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | EFFECT | Notice of Effectiveness |
| Apr 24, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 10, 2024 | EFFECT | Notice of Effectiveness |
| Apr 10, 2024 | 424B3 | Prospectus |